Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 19/20 | 1.00 |
| ▸ | PDK2 | Q15119 | 19/20 | 1.00 |
| ▸ | PDK3 | Q15120 | 19/20 | 1.00 |
| ▸ | PDK4 | Q16654 | 19/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5710351 | 1.00 | PDK1 (1.00) | PDK1PDK2PDK3PDK4MEN1 | |
| SCHEMBL6348877 | 0.88 | PDK1 (1.00) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL5735974 | 0.88 | PDK1 (1.00) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL5710226 | 0.87 | PDK1 (0.76) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL5710224 | 0.87 | PDK1 (0.76) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL6352865 | 0.87 | PDK1 (0.76) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL5710228 | 0.85 | PDK1 (0.74) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL14411794 | 0.85 | PDK1 (0.74) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL5710232 | 0.85 | PDK1 (0.74) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL5710321 | 0.85 | PDK1 (0.74) | PDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1214295-B1 | HYDROXYACETAMIDOBENZENESULPHONAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| EP-1214296-B1 | SUBSTITUTED N-PHENYL 2-HYDROXY-2-METHYL-3,3,3-TRIFLUOROPROPANAMIDE DERIVATIVES WHICH ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY | ASTRAZENECA AB (SE) | 2004-03-24 | — | — | EP | disclosed |
| US-6689909-B1 | TREATMENT OF DISEASE STATE SELECTED FROM THE GROUP CONSISTING OF DIABETES MELLITUS, PERIPHERAL VASCULAR DISEASE AND MYOCARDIAL ISCHAEMIA | ASTRAZENECA AB (SE) | 2004-02-10 | — | — | US | disclosed |
| US-6552225-B1 | Such as n-(2,3-dichloro-4-(methylaminosulphonyl)phenyl)-3,3,3-trifluoro-2-hydroxy-2 -methylpropanamide; diabetes, obesity, lactic acidaemia | ASTRAZENECA AB (SE) | 2003-04-22 | — | — | US | disclosed |
| EP-1214296-A1 | SUBSTITUTED N-PHENYL 2-HYDROXY-2-METHYL-3,3,3-TRIFLUOROPROPANAMIDE DERIVATIVES WHICH ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY | AstraZeneca AB (SE) | 2002-06-19 | — | — | EP | disclosed |
| EP-1214295-A2 | HYDROXYACETAMIDOBENZENESULPHONAMIDE DERIVATIVES | AstraZeneca AB (SE) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001017955-A2 | HYDROXYACETAMIDOBENZENESULPHONAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-15 | — | — | WO | disclosed |
| WO-2001017956-A1 | SUBSTITUTED N-PHENYL 2-HYDROXY-2-METHYL-3,3,3-TRIFLUOROPROPANAMIDE DERIVATIVES WHICH ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY | ASTRAZENECA AB (SE) | 2001-03-15 | — | — | WO | disclosed |